Approved Drug Licensing & Out-Licensing Deal Benchmarks

Licensing deals for approved drugs represent the most de-risked end of the biopharma deal spectrum, with total deal values reaching $5.7B median. Upfront payments are substantial, ranging from $1.5B to $2.7B, reflecting the eliminated development risk and existing revenue stream. These deals are driven by geographic expansion, commercial optimization, and portfolio rationalization strategies.

Milestone structures for approved drug deals shift heavily toward commercial milestones ($2.5B), with development milestones ($180M) focused on label expansions and supplemental indications. Regulatory milestones of $898M reward approvals in new territories or additional indications.

Royalty rates for approved drug licensing typically range from 19.3% to 30% at the base tier, with escalation to 34% on peak sales. The 37/63 upfront/milestone split reflects the minimal remaining risk. Patent life remaining, competitive landscape dynamics, and generic/biosimilar exposure timelines are critical value determinants.